NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said today that it intends to transfer its stock from the American Stock Exchange to the New York Stock Exchange on or around Oct. 24.
The firm’s Class A common stock will continue to trade under the ticker BIO, and its Class B common stock will continue to trade under the ticker BIOb.
Bio-Rad President and CEO Norman Schwartz said in a statement that the firm’s shareholders “will benefit from the NYSE’s brand, reputation, and trading efficiencies.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.